<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01883427</url>
  </required_header>
  <id_info>
    <org_study_id>GObarn2013</org_study_id>
    <nct_id>NCT01883427</nct_id>
  </id_info>
  <brief_title>Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children</brief_title>
  <official_title>Placebo Controlled Study Among Children Below Four Years of Age, Investigating Whether a Glucose Oxidase Nasal Spray Can Reduce Days With Upper Respiratory Tract Infection Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krister Tano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Umeå University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate if use of glucosoxidas nasal spray can reduce the number of days with upper
      respiratory tract infections in children beyond 4 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children below 4 years of age and in public day care were invited to participate in this
      prospective study. The children started with a visit to an ENT doctor and after inclusion the
      children started to spray twice daily with glucose oxidase+glucose or only saline+glucose for
      3 months. During this period the parents were asked to fill in a home protocol recording
      upper respiratory tract symptoms as: rhinitis, cough, fever, ear ache. After 6 weeks and 12
      weeks the children had scheduled visits to the ENT department, where an ENT doctor examined
      the throat, nasal cavity and the ear drums for otitis media. After 12 weeks of treatment a
      nasopharyngeal swab was taken for bacterial culture.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Respiratory Infectious Symptoms</measure>
    <time_frame>3 months of recording</time_frame>
    <description>Days with upper respiratory tract infection symptoms during a 3 months period are recorded in a home protocol by the parents of the children.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Upper Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Placebo: Saline+glucose nasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received nasal spray containing both saline+glucose twice daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasal spray with glucose oxidase+glucose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nasal spray in a bag-on-valve device with 50U/ml containing both glucose oxidase + 5% glucose in isotone saline. Dosage: One puff in each nostril twice daily for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo containing saline+glucose</description>
    <arm_group_label>Placebo: Saline+glucose nasal spray</arm_group_label>
    <other_name>Baxter Rehydrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucose oxidase</intervention_name>
    <description>a hydrogen peroxide producing enzyme that creates an acidous environment to which rhinoviruses are sensitive.</description>
    <arm_group_label>Nasal spray with glucose oxidase+glucose</arm_group_label>
    <other_name>G2133, Sigmaaldrich</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children below 4 years of age

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Westman, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Västernorrlands Landsting</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie Ryding, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Jämtlands Landsting</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anders Niklasson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Norrbottens Landsting</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helena Toolanen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Norrbottens Landsting</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Öronmottagningen</name>
      <address>
        <city>Piteå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Öronmottagningen</name>
      <address>
        <city>Sunderbyn</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Öronmottagningen</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Öronmottagningen</name>
      <address>
        <city>Östersund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2013</study_first_submitted>
  <study_first_submitted_qc>June 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2013</study_first_posted>
  <results_first_submitted>April 16, 2015</results_first_submitted>
  <results_first_submitted_qc>December 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 11, 2016</results_first_posted>
  <last_update_submitted>December 7, 2015</last_update_submitted>
  <last_update_submitted_qc>December 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Umeå University</investigator_affiliation>
    <investigator_full_name>Krister Tano</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Days with URTI symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Saline+Glucose Nasal Spray</title>
          <description>Nasal spray with saline+glucose twice daily for 3 months
Saline + glucose: A bag on valve nasal spray device containing isotone saline and 5% glucose</description>
        </group>
        <group group_id="P2">
          <title>Nasal Spray With Glucose Oxidase+Glucose</title>
          <description>Nasal spray in a bag-on-valve device with 50U/ml glucose oxidase + 5% glucose in isotone saline. Dosage: One puff in each nostril twice daily for 3 months.
Glucose oxidase: Glucose oxidase is a hydrogen peroxide producing enzyme, imitating the inhibitory effects of the normal bacterial flora of the nasopharynx</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Pre-school children</population>
      <group_list>
        <group group_id="B1">
          <title>Saline+Glucose Nasal Spray</title>
          <description>Nasal spray with saline+glucose twice daily for 3 months
Saline + glucose: A bag on valve nasal spray device containing isotone saline and 5% glucose</description>
        </group>
        <group group_id="B2">
          <title>Nasal Spray With Glucose Oxidase+Glucose</title>
          <description>Nasal spray in a bag-on-valve device with 50U/ml glucose oxidase + 5% glucose in isotone saline. Dosage: One puff in each nostril twice daily for 3 months.
Glucose oxidase: Glucose oxidase is a hydrogen peroxide producing enzyme, imitating the inhibitory effects of the normal bacterial flora of the nasopharynx</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" lower_limit="14" upper_limit="43"/>
                    <measurement group_id="B2" value="27" lower_limit="11" upper_limit="44"/>
                    <measurement group_id="B3" value="28" lower_limit="11" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Respiratory Infectious Symptoms</title>
        <description>Days with upper respiratory tract infection symptoms during a 3 months period are recorded in a home protocol by the parents of the children.</description>
        <time_frame>3 months of recording</time_frame>
        <population>Only a total of 40 Children fulfilled the study, which means that the Power are to low.</population>
        <group_list>
          <group group_id="O1">
            <title>Saline+Glucose Nasal Spray</title>
            <description>Nasal spray with saline+glucose twice daily for 3 months
Saline + glucose: A bag on valve nasal spray device containing isotone saline and 5% glucose</description>
          </group>
          <group group_id="O2">
            <title>Nasal Spray With Glucose Oxidase+Glucose</title>
            <description>Nasal spray in a bag-on-valve device with 50U/ml glucose oxidase + 5% glucose in isotone saline. Dosage: One puff in each nostril twice daily for 3 months.
Glucose oxidase: Glucose oxidase is a hydrogen peroxide producing enzyme, imitating the inhibitory effects of the normal bacterial flora of the nasopharynx</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Infectious Symptoms</title>
          <description>Days with upper respiratory tract infection symptoms during a 3 months period are recorded in a home protocol by the parents of the children.</description>
          <population>Only a total of 40 Children fulfilled the study, which means that the Power are to low.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days with URTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="4"/>
                    <measurement group_id="O2" value="13" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days with rhinitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="6"/>
                    <measurement group_id="O2" value="13" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days with cough and rhinitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="5"/>
                    <measurement group_id="O2" value="8" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>days with fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="3"/>
                    <measurement group_id="O2" value="5" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Too few included to reach power</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Not significant</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the study period of 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Saline+Glucose Nasal Spray</title>
          <description>Nasal spray with saline+glucose twice daily for 3 months
Saline + glucose: A bag on valve nasal spray device containing isotone saline and 5% glucose</description>
        </group>
        <group group_id="E2">
          <title>Nasal Spray With Glucose Oxidase+Glucose</title>
          <description>Nasal spray in a bag-on-valve device with 50U/ml glucose oxidase + 5% glucose in isotone saline. Dosage: One puff in each nostril twice daily for 3 months.
Glucose oxidase: Glucose oxidase is a hydrogen peroxide producing enzyme, imitating the inhibitory effects of the normal bacterial flora of the nasopharynx</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>local side effects</sub_title>
                <description>Local side effects in the nasal cavity</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We wanted 200 Children but only 40 fulfilled the study, which make the results hard to evaluate.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>MD, PhD Krister Tano</name_or_title>
      <organization>Umeå University</organization>
      <phone>0046705569043</phone>
      <email>krister.tano@umu.se</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

